PZ Cormay recorded PLN 1.64 million of consolidated net profit attributable to shareholders of the parent company in 2021 compared to a loss of PLN 12.67 million a year earlier, the company said in the report. The operating loss was PLN 68 thousand. PLN as compared to PLN 7.3 million loss a year earlier.
The EBITDA result amounted to PLN 4.27 million against PLN 2.99 million loss a year earlier. Consolidated sales revenues reached PLN 84.73 million in 2021 compared to PLN 65.29 million a year earlier.
On a standalone basis, the net loss in 2021 amounted to PLN 0.14 million, compared to a loss of PLN 7.79 million a year earlier.
“In 2022, we plan to offer our customers four new devices: 3 hematology analyzers for human blood testing and Equisse, the largest biochemical analyzer in our offer. The last of the above-mentioned devices, developed by the Company, in the first quarter of this year. has successfully completed many months of internal and external tests, enabling us to report it to the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, necessary for the start of its commercialization.
The first mass-produced copies of the analyzer will be delivered to our warehouses in the coming months. At the beginning of the third quarter of 2022, they will be offered to selected Polish and foreign clients. The international premiere of the analyzer will take place in autumn during this year’s Medica trade fair in Dusseldorf, ”we read in the letter of the president of Flavio Finotello. PZ Cormay is a manufacturer of diagnostic reagents and a distributor of medical equipment. The company has been listed on the main market of the WSE since 2008.